{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:48:27Z","timestamp":1773287307947,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13300-017-0238-7","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:44:02Z","timestamp":1487929442000},"page":"385-399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study"],"prefix":"10.1007","volume":"8","author":[{"given":"Akiko","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Harashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Fukushige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminori","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,24]]},"reference":[{"key":"238_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"238_CR2","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/dc16-S010","volume":"39","author":"American Diabetes Association","year":"2016","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142016. Diabetes Care. 2016;39[Suppl 1]:S52\u20139.","journal-title":"Diabetes Care"},{"key":"238_CR3","doi-asserted-by":"publisher","first-page":"g5459","DOI":"10.1136\/bmj.g5459","volume":"349","author":"AC Tricco","year":"2014","unstructured":"Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ. 2014;349:g5459.","journal-title":"BMJ"},{"key":"238_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2014.17","volume":"10","author":"VA Fonseca","year":"2014","unstructured":"Fonseca VA, Haggar MA. Achieving glycaemic targets with basal insulin in type 2 diabetes by individualizing treatment. Nat Rev Endocrinol. 2014;10:276\u201381.","journal-title":"Nat Rev Endocrinol."},{"key":"238_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/dmrr.2469","volume":"30","author":"DR Owens","year":"2014","unstructured":"Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2014;30:104\u201319.","journal-title":"Diabetes Metab Res Rev."},{"key":"238_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.diabet.2010.03.006","volume":"36","author":"PY Benhamou","year":"2010","unstructured":"Benhamou PY, Gamier C, Debay I, et al. Basal insulin dose in 40 type 1 diabetic patients remains stable 1\u00a0year after educational training in flexible insulin therapy. Diabetes Metab. 2010;36:369\u201374.","journal-title":"Diabetes Metab."},{"key":"238_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4158\/EP14079.OR","volume":"21","author":"SK Garg","year":"2015","unstructured":"Garg SK, Admane K, Freemantle N, et al. Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational ATLAS study. Endocr Pract. 2015;21:143\u201357.","journal-title":"Endocr Pract."},{"key":"238_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1463-1326.2011.01395.x","volume":"13","author":"M Evans","year":"2011","unstructured":"Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13:677\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"238_CR9","unstructured":"Sanofi-Aventis. Last update 2015. Lantus (insulin glargine U100) label Japan. 2017. http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/780069_2492416G2024_1_13 . Accessed 29 Jan 2017."},{"key":"238_CR10","unstructured":"Sanofi-Aventis. Last update 2016. Lantus (insulin glargine U100) label Europe. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000284\/WC500036082.pdf . Accessed 29 Jan 2017."},{"key":"238_CR11","unstructured":"Sanofi-Aventis. Last update 2015. Lantus (insulin glargine U100) label USA. 2017. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021081s063lbl.pdf . Accessed 29 Jan 2017."},{"key":"238_CR12","unstructured":"Novo Nordisk A\/S. Last updated 2013. Levemir (insulin detemir) label Japan. 2017. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/620023_2492417G1030_1_09 . Accessed 29 Jan 2017."},{"key":"238_CR13","unstructured":"Novo Nordisk A\/S. Last updated 2016. Levemir (insulin detemir) label Europe. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000528\/WC500036662.pdf . Accessed 29 Jan 2017."},{"key":"238_CR14","unstructured":"Novo Nordisk A\/S. Last updated 2015. Levemir (insulin detemir) label USA. 2017. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021536s031s051lbl.pdf . Accessed 29 Jan 2017."},{"key":"238_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682\u20139.","journal-title":"Diabet Med"},{"key":"238_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/dme.12128","volume":"30","author":"MJ Davies","year":"2013","unstructured":"Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30:512\u201324.","journal-title":"Diabet Med"},{"key":"238_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1089\/dia.2010.0156","volume":"13","author":"D Xing","year":"2011","unstructured":"Xing D, Kollman C, Beck RW, et al. Juvenile diabetes research foundation continuous glucose monitoring study group. optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. Diabetes Technol Ther. 2011;13:351\u20138.","journal-title":"Diabetes Technol Ther."},{"key":"238_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2337\/diacare.23.7.943","volume":"23","author":"DJ Toobert","year":"2000","unstructured":"Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000;23:943\u201350.","journal-title":"Diabetes Care"},{"key":"238_CR19","first-page":"1","volume":"49","author":"M Daitoku","year":"2006","unstructured":"Daitoku M, Honda I, Okumiya A, et al. Validity and reliability of the Japanese translated \u201cThe Summary of Diabetes Self-care Activities Measure\u201d. J Japan Diabetes Soc. 2006;49:1\u20139 (in Japanese).","journal-title":"J Japan Diabetes Soc."},{"key":"238_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2337\/diacare.18.6.754","volume":"18","author":"WH Polonsky","year":"1995","unstructured":"Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetes-related distress. Diabetes Care. 1995;18:754\u201360.","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"238_CR21","first-page":"A319","volume":"48","author":"H Ishii","year":"1999","unstructured":"Ishii H, Welch G, Jacobson A, et al. The Japanese version of the problem area in diabetes scale: a clinical and research tool for the assessment of emotional functioning among diabetes patients. Diabetes. 1999;48 (Suppl 1):A319.","journal-title":"Diabetes"},{"key":"238_CR22","volume-title":"Info package: mastering depression in primary care","author":"World Health Organization","year":"1998","unstructured":"World Health Organization. Info package: mastering depression in primary care. Frederiksborg, Denmark: WHO Regional Office of Europe, Psychiatric Research Unit; 1998."},{"key":"238_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1464-5491.1990.tb01421.x","volume":"7","author":"C Bradley","year":"1990","unstructured":"Bradley C, Lewis KS. Measurements of psychological wellbeing and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med. 1990;7:445\u201351.","journal-title":"Diabet Med"},{"key":"238_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1819.2007.01619.x","volume":"61","author":"S Awata","year":"2007","unstructured":"Awata S, Bech P, Yoshida S, et al. Reliability and validity of the Japanese version of the World Health Organization-five well-being index in the context of detecting depression in diabetic patients. Psychiatry Clin Neurosci. 2007;61:112\u20139.","journal-title":"Psychiatry Clin Neurosci"},{"key":"238_CR25","volume-title":"Practice guideline for the treatment for diabetes in Japan 2016","author":"Japan Diabetes Society","year":"2016","unstructured":"Japan Diabetes Society. Practice guideline for the treatment for diabetes in Japan 2016. Tokyo: Nankodo; 2016."},{"key":"238_CR26","unstructured":"Novo Nordisk A\/S. Last updated 2016. Tresiba (insulin degludec) label Japan. 2017. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/620023_2492419G1021_1_08 Accessed 29 Jan 2017."},{"key":"238_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.diabres.2016.07.011","volume":"120","author":"MB Gomes","year":"2016","unstructured":"Gomes MB, Negrato CA. Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A nationwide survey in Brazil. Diabetes Res Clin Pract. 2016;120:47\u201355.","journal-title":"Diabetes Res Clin Pract"},{"key":"238_CR28","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1185\/03007995.2012.743458","volume":"28","author":"M Brod","year":"2012","unstructured":"Brod M, Rana A, Barnett AH. Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Curr Med Res Opin. 2012;28:1933\u201346.","journal-title":"Curr Med Res Opin"},{"key":"238_CR29","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1185\/03007995.2012.743457","volume":"28","author":"M Brod","year":"2012","unstructured":"Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin. 2012;28:1947\u201358.","journal-title":"Curr Med Res Opin"},{"key":"238_CR30","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1177\/1060028015597915","volume":"49","author":"J Goldman","year":"2015","unstructured":"Goldman J, White JR Jr. New insulin glargine 300 U\/mL for the treatment of type 1 and type 2 diabetes mellitus. Ann Pharmacother. 2015;49:1153\u201361.","journal-title":"Ann Pharmacother"},{"key":"238_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/dia.2015.0290","volume":"18","author":"MC Riddle","year":"2016","unstructured":"Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U\/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016;18:252\u20137.","journal-title":"Diabetes Technol Ther."},{"key":"238_CR32","unstructured":"Sanofi-Aventis. Last update 2015. Lantus XR (insulin glargine U300) label Japan. 2017. http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/780069_2492416G3020_1_02 . Accessed 29 Jan 2017."},{"key":"238_CR33","unstructured":"Sanofi-Aventis. Last update 2016. Toujeo (insulin glargine U300) label Europe. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000309\/WC500047935.pdf . Accessed 29 Jan 2017."},{"key":"238_CR34","unstructured":"Sanofi-Aventis. Last update 2015. Toujeo (insulin glargine U300) label USA. 2017. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206538s000lbl.pdf . Accessed 29 Jan 2017."},{"key":"238_CR35","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/dom.12114","volume":"15","author":"RG Josse","year":"2013","unstructured":"Josse RG, Woo V. Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin. Diabetes Obes Metab. 2013;15:1077\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"238_CR36","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Nosek L, B\u00f8ttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944\u201350.","journal-title":"Diabetes Obes Metab"},{"key":"238_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/jdi.12502","volume":"7","author":"T Kadowaki","year":"2016","unstructured":"Kadowaki T, Jinnouchi H, Kaku K, Hersl\u00f8v ML, Hyllested-Winge J, Nakamura S. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: a randomized, 26-week, treat-to-target trial. J Diabetes Investig. 2016;7:711\u20137.","journal-title":"J Diabetes Investig."},{"key":"238_CR38","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1210\/jc.2012-3249","volume":"98","author":"C Mathieu","year":"2013","unstructured":"Mathieu C, Hollander P, Miranda-Palma B, NN1250-3770 (BEGIN: Flex T1) Trial Investigators, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"238_CR39","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"L Meneghini","year":"2013","unstructured":"Meneghini L, Atkin SL, Gough SC, NN1250-3668 (BEGIN FLEX) Trial Investigators, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858\u201364.","journal-title":"Diabetes Care"},{"key":"238_CR40","unstructured":"Novo Nordisk A\/S. Last updated 2015. Tresiba (insulin degludec) label Eupopa. 2017 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EP.AR_-_Product_Information\/human\/002498\/WC500138940.pdf . Accessed 29 Jan 2017."},{"key":"238_CR41","unstructured":"Novo Nordisk A\/S. Last updated 2015. Tresiba (insulin degludec) label USA. 2017. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/203314lbl.pdf . Accessed 29 Jan 2017."},{"key":"238_CR42","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3111\/13696998.2013.846262","volume":"16","author":"M Evans","year":"2013","unstructured":"Evans M, Jensen HH, B\u00f8gelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013;16:1357\u201365.","journal-title":"J Med Econ."},{"key":"238_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/cer.15.10","volume":"4","author":"M Evans","year":"2015","unstructured":"Evans M, McEwan P. Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice. J Comp Eff Res. 2015;4:279\u201386.","journal-title":"J Comp Eff Res"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0238-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-017-0238-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0238-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T19:01:44Z","timestamp":1658689304000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-017-0238-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,24]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["238"],"URL":"https:\/\/doi.org\/10.1007\/s13300-017-0238-7","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,24]]},"assertion":[{"value":"7 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}